Evidence map›Paper›PMID 26272601›Full record

ArticleJournal of neuro-oncology2015

miR-429 inhibits glioma invasion through BMK1 suppression.

Weiyi Chen, Baogang Zhang, Wenjun Guo, Linlin Gao, Lihong Shi, Hongli Li, Shijun Lu, Yuqing Liu, Xiaolong Li

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Impact of ERK5 on the Hallmarks of Cancer.International journal of molecular sciences · 2019
    Review
  12. Article
  13. The miR-200 family: multiple effects on gliomas.Cancer management and research · 2018
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Weiyi ChenDepartment of Pathology, Weifang Medical University, Weifang, 261053, People's Republic of China.
Baogang ZhangDepartment of Pathology, Weifang Medical University, Weifang, 261053, People's Republic of China. zbg0903@hotmail.com.
Wenjun GuoDepartment of Pathology, Weifang Medical University, Weifang, 261053, People's Republic of China.
Linlin GaoDepartment of Internal Medicine, NO.3, Laixi Municipal Hospital, Laixi, 266600, People's Republic of China.
Lihong ShiDepartment of Pharmacology, Weifang Medical University, Weifang, 261053, People's Republic of China.
Hongli LiDepartment of Medicine Research Center, Weifang Medical University, Weifang, 261053, People's Republic of China.
Shijun LuDepartment of Pathology, Weifang Medical University, Weifang, 261053, People's Republic of China.
Yuqing LiuDepartment of Pathology, Weifang Medical University, Weifang, 261053, People's Republic of China.
Xiaolong LiDepartment of Pathology, Weifang Medical University, Weifang, 261053, People's Republic of China.
Weifang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this research was to examine the relationship between big mitogen-activated protein kinase 1 (BMK1) and miRNA miR-429 and to determine the effect of miR-429 on glioma invasiveness. Immunohistochemistry was used to evaluate BMK1 expression in glioma tissues. Real-time PCR was used to measure the expression of miR-429 and other RNAs. Western blot was used to detect the expression of BMK1 and other related proteins. Wound healing, Matrigel invasion, and chemotaxis assays were performed to detect the invasion and migration of glioma cell lines. The actual binding site of miR-429 to the 3' untranslated region of BMK1 was confirmed by luciferase assay and RNA immunoprecipitation. BMK1 expression was associated with the World Health Organization grading of glioma and inversely correlated with patient survival. Suppression of BMK1 inhibited the migration and invasion of glioma cells by interfering with mesenchymal transition. Additionally, hepatocyte growth factor-induced GSK3β phosphorylation was suppressed through BMK1 knockdown. Interestingly, our findings validated a novel role for miR-429 in suppressing the migration and invasion of glioma by directly inhibiting BMK1 expression. We also found that miR-429 expression in glioma cells and tissues was lower than that in normal cells and adjacent non-neoplastic tissues, and miR-429 overexpression inhibited invasive activity of glioma cells both in vitro and in vivo. Furthermore, our data validated that miR-429 downregulation was due to the hypermethylation of its promoter region. Our results indicated that BMK1 modulation by miR-429 has an important function in glioma invasion both in vitro and in vivo.

Indexed as

AdultAgedAged, 80 and overAnimalsBrain NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticGliomaHumansMaleMesodermMice, SCIDMicroRNAsMiddle AgedMitogen-Activated Protein Kinase 1MicroRNAsMIRN429 microRNA, humanMitogen-Activated Protein Kinase 1BMK1GliomaInvasionmiR-429

Identifiers

PMID26272601
OpenAlexW1160727022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.